[1] Lu J, Li J, Lin Z, et al.Reprogramming of TAMs via the STAT3/CD47-SIRPα axis promotes acquired resistance to EGFR-TKIs in lung cancer[J]. Cancer Lett, 2023, 564: 216205.
[2] Shi W, Cheng Y, Zhu H, et al.Metabolomics and lipidomics in non-small cell lung cancer[J]. Clin chim acta, 2024, 555: 117823.
[3] Babuta J, Hall Z, Athersuch T.Dysregulated Metabolism in EGFR-TKI Drug Resistant Non-Small-Cell Lung Cancer: A Systematic Review[J]. Metabolites, 2022, 12(7):644.
[4] Ibusuki R, Iwama E, Shimauchi A, et al.TP53 gain-of-function mutations promote osimertinib resistance via TNF-α-NF-κB signaling in EGFR-mutated lung cancer[J]. NPJ Precis Oncol, 2024, 8(1): 60.
[5] Passaro A, Jänne PA, Mok T, et al.Overcoming therapy resistance in EGFR-mutant lung cancer[J]. Nat Cancer, 2021, 2(4): 377-391.
[6] You Q, Wang J, Yu Y, et al.The histone deacetylase SIRT6 promotes glycolysis through the HIF-1α/HK2 signaling axis and induces erlotinib resistance in non-small cell lung cancer[J]. Apoptosis, 2022, 27(11-12): 883-898.
[7] Lin Z, Li J, Zhang J, et al.Metabolic Reprogramming Driven by IGF2BP3 Promotes Acquired Resistance to EGFR Inhibitors in Non-Small Cell Lung Cancer[J]. Cancer res, 2023, 83(13): 2187-2207.
[8] Luo Y, Yang Y, Peng P, et al.Cholesterol synthesis disruption combined with a molecule-targeted drug is a promising metabolic therapy for EGFR mutant non-small cell lung cancer[J]. Transl lung cancer res, 2021, 10(1): 128-142.
[9] Ding J, Ding X, Leng Z.LPCAT1 promotes gefitinib resistance via upregulation of the EGFR/PI3K/AKT signaling pathway in lung adenocarcinoma[J]. J Cancer, 2022, 13(6): 1837-1847.
[10] Xiao Z, Li M, Zhang X, et al.TRIP13 overexpression promotes gefitinib resistance in non-small cell lung cancer via regulating autophagy and phosphorylation of the EGFR signaling pathway[J]. Oncol rep, 2023, 49(5): 84.
[11] Peralta-Arrieta I, Trejo-Villegas OA, Armas-López L, et al.Failure to EGFR-TKI-based therapy and tumoural progression are promoted by MEOX2/GLI1-mediated epigenetic regulation of EGFR in the human lung cancer[J]. Eur j cancer, 2022, 160: 189-205.
[12] Ding D, Xu C, Zhang J, et al.Revealing underlying regulatory mechanisms of LINC00313 in Osimertinib-resistant LUAD cells by ceRNA network analysis[J]. Transl Oncol, 2024, 43: 101895.
[13] Wang G, Li T, Wan Y, et al.MYC expression and fatty acid oxidation in EGFR-TKI acquired resistance[J]. Drug resist update, 2024, 72: 101019.
[14] Musharraf SG, Mazhar S, Choudhary MI, et al.Plasma metabolite profiling and chemometric analyses of lung cancer along with three controls through gas chromatography-mass spectrometry[J]. Sci Rep, 2015, 5: 8607.
[15] Fang Y, Li X, Cheng H, et al.ANGPTL4 Regulates Lung Adenocarcinoma Pyroptosis and Apoptosis via NLRP3\ASC\Caspase 8 Signaling Pathway to Promote Resistance to Gefitinib[J]. J oncol, 2022, 2022: 3623570.
[16] Tambay V, Raymond VA, Bilodeau M.MYC Rules: Leading Glutamine Metabolism toward a Distinct Cancer Cell Phenotype[J]. Cancers (Basel), 2021, 13(17): 4484.
[17] Lahalle A, Lacroix M, De BlasioC, et al. The p53 Pathway and Metabolism: The Tree That Hides the Forest[J]. Cancers (Basel), 2021, 13(1): 133.
[18] Zheng Q, Dong H, Mo J, et al.A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance[J]. Theranostics, 2021, 11(2): 824-840.
[19] Yu F, Yu C, Li F, et al.Wnt/β-catenin signaling in cancers and targeted therapies[J]. Signal transduct tar, 2021, 6(1): 307.
[20] Yi Y, Li P, Huang Y, et al.P21-activated kinase 2-mediated β-catenin signaling promotes cancer stemness and osimertinib resistance in EGFR-mutant non-small-cell lung cancer[J]. Oncogene, 2022, 41(37): 4318-4329.
[21] Kim S, Jeon JS, Choi YJ, et al.Heterogeneity of glutamine metabolism in acquired-EGFR-TKI-resistant lung cancer[J]. Life sci, 2022, 291: 120274.
[22] Zhang WC, Skiados N, Aftab F, et al.MicroRNA-21 guide and passenger strand regulation of adenylosuccinate lyase-mediated purine metabolism promotes transition to an EGFR-TKI-tolerant persister state[J]. Cancer gene ther, 2022, 29(12): 1878-1894.
[23] Nie M, Chen N, Pang H, et al.Targeting acetylcholine signaling modulates persistent drug tolerance in EGFR-mutant lung cancer and impedes tumor relapse[J]. J clin invest, 2022, 132(20): e160152.
[24] Liu YN, Tsai MF, Wu SG, et al.CD44s and CD44v8-10 isoforms confer acquired resistance to osimertinib by activating the ErbB3/STAT3 signaling pathway[J]. Life sci, 2024, 336: 122345.
[25] Zhang Z, Lee JC, Lin L, et al.Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer[J]. Nat genet, 2012, 44(8): 852-860.
[26] Sun Q, Lu Z, Zhang Y, et al.Integrin β3 Promotes Resistance to EGFR-TKI in Non-Small-Cell Lung Cancer by Upregulating AXL through the YAP Pathway[J]. Cells, 2022, 11(13): 2078.
[27] Han R, Lin C, Lu C, et al.Sialyltransferase ST3GAL4 confers osimertinib resistance and offers strategies to overcome resistance in non-small cell lung cancer[J]. Cancer lett, 2024, 588: 216762.
[28] Wang Y, Wei J, Feng L, et al.Aberrant m5C hypermethylation mediates intrinsic resistance to gefitinib through NSUN2/YBX1/QSOX1 axis in EGFR-mutant non-small-cell lung cancer[J]. Mol Cancer, 2023, 22(1): 81.
[29] Ni Y, Liu J, Zeng L, et al.Natural product manoalide promotes EGFR-TKI sensitivity of lung cancer cells by KRAS-ERK pathway and mitochondrial Ca2+ overload-induced ferroptosis[J]. Front Pharmacol, 2022, 13: 1109822.
[30] Park W, Han JH, Wei S, et al.Natural Product-Based Glycolysis Inhibitors as a Therapeutic Strategy for Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer[J]. Int J Mol Sci, 2024, 25(2): 807. |
